BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

This study is currently recruiting participants.
Verified March 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01669174
First received: March 1, 2012
Last updated: March 26, 2014
Last verified: March 2014

March 1, 2012
March 26, 2014
September 2012
January 2015   (final data collection date for primary outcome measure)
Change in thigh muscle volume compare to placebo as measured by MRI [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Change in thigh muscle volume compare to placebo as measured by MRI [ Time Frame: 4, 8, 16 and 24 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01669174 on ClinicalTrials.gov Archive Site
  • Change in 6 minute walk distance compared to placebo [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Safety and tolerability of BYM338 in COPD patients with cachexia [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic profile and immunogenicity response to BYM338 in COPD patients with cachexia [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Number of participants with adverse events as a measure of safety and tolerability of BYM338 in COPD patients with cachexia [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Change in 6 minute walk distance compared to placebo [ Time Frame: 4, 8, 12, 16 and 24 weeks ] [ Designated as safety issue: No ]
  • Number of Participants with Adverse Events as a Measure of Safety and tolerability of 30 mg/kg of BYM338 in COPD patients with cachexia [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic profile and immunogenicity response to a single 30 mg/kg infusion of BYM338 in COPD patients with cachexia [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia

This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo. The study will last for approximately 24 weeks.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
  • Drug: Placebo
  • Drug: BYM338
    BYM338
  • Experimental: BYM338
    Intervention: Drug: BYM338
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
January 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Written informed consent must be obtained before any assessment is performed.
  • Males and females ages 40 to 80 years
  • Smoking history of at least 10 pack-years
  • Diagnosis of COPD according to GOLD guidelines (GOLD, 2010), with a post-bronchodilator FEV¬1 < 80% predicted and FEV1/FVC ratio < 0.70
  • BMI <20 kg/m2 or skeletal muscle mass index by DXA < 7.25 kg/m2 for men or <5.45 kg/m2 for women.
  • In general stable health, including managed COPD, by past medical history, physical examination, vital signs at baseline as determined by the investigator.

Exclusion criteria:

  • Patients with MRC dyspnoea grade 5 (i.e. patients too breathless to leave the house or breathless when dressing)
  • Plans for lung transplantation or lung reduction surgery within four months of enrollment
  • Patients participating in a formal pulmonary rehabilitation program within 3 months of dosing
  • History of malignancy of any organ system (other than excised non-melanomatous carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • Diseases other than cancer known to cause cachexia or muscle atrophy, including but not limited to congestive heart failure of any stage, chronic kidney disease (estimated GFR < 30 mL/min using the MDRD equation), rheumatoid arthritis, primary myopathy, stroke, HIV infection, tuberculosis or other chronic infection, uncontrolled diabetes mellitus, etc.
  • Inflammatory bowel disease, celiac disease, short bowel syndrome, pancreatic insufficiency
  • Use of any prescription drugs known to affect muscle mass, including androgen supplements, anti-androgens (such as LHRH agonists), anti-estrogens (tamoxifen, etc.) recombinant human growth hormone (rhGH), insulin, oral beta agonists, megestrol acetate, dronabinol, metformin, etc.
  • Hemoglobin concentration below 11.0 g/dL at screening.
  • Liver disease or liver injury.
  • Use of other investigational drugs at the time of enrollment, or within 30 days and for any other limitation of participation in an investigational trial based on local regulations.
  • Women of child-bearing potential.

Other protocol-defined inclusion/exclusion criteria may apply

Both
40 Years to 80 Years
Yes
Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals
United States,   Netherlands,   Romania,   United Kingdom
 
NCT01669174
CBYM338X2204, 2011-000461-12
Yes
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP